Clearside Biomedical Inc. (NASDAQ: CLSD) went public Thursday in a $50.4 million IPO.
Its IPO of 7.2 million shares at $7 each is less than half of what it originally sought. According to the Wall Street Journal, the company originally planned to sell 4 million shares between $14 and $16 a share.
The Alpharetta, Ga.-based late stage biopharmaceutical company announced in January it would go public.
Clearside develops drug therapies to treat blinding diseases of the eye using a microinjector to reach diseased tissue.